| alirocumab vs ezetimibe (on top statin) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| death from all causes as adverse event | 0.33 [0.03 3.17] | p=1.00 | 0 | 410 | 2 | ODYSSEY OPTIONS I,ODYSSEY OPTIONS II, | | serious adverse events | 0.65 [0.29 1.50] | p=1.00 | 0 | 410 | 2 | ODYSSEY OPTIONS I,ODYSSEY OPTIONS II, | | cardiovascular events as adverse event | no data | | neurological SAE | no data | | Neurocognitive disorder | no data | | Muscle-related adverse events | no data | | cardiovascular death as adverse event | 0.25 [0.03 2.28] | p=1.00 | 0 | 410 | 2 | ODYSSEY OPTIONS I,ODYSSEY OPTIONS II, | | myocardial infarction as adverse event | no data | | unstable angina as adverse death | no data | | cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | Coronary event | no data | | Coronary death | no data | | Allergic reactions | no data | | All cause death | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| alirocumab vs placebo (on top statins) | cardiovascular events by 13% (fully demonstrated) Coronary event by 12% (fully demonstrated) suggested death from all causes as adverse event by 62% (not demonstrated) suggested cardiovascular death as adverse event by 62% (not demonstrated) suggested myocardial infarction as adverse event by 56% (not demonstrated) suggested All cause death by 15% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| death from all causes as adverse event | 0.38 [0.15 0.96] | p=0.04 | 0 | 3735 | 5 | ODYSSEY Long-Term,ODYSSEY Alternative,ODYSSEY HIGH FH ,ODYSSEY COMBO,ODYSSEY COMBO II, | | serious adverse events | 0.98 [0.82 1.18] | p=1.00 | 0 | 3732 | 5 | ODYSSEY Long-Term,ODYSSEY Alternative,ODYSSEY HIGH FH ,ODYSSEY COMBO,ODYSSEY COMBO II, | | cardiovascular events as adverse event | 0.91 [0.61 1.36] | p=1.00 | 0 | 2341 | 1 | ODYSSEY Long-Term, | | neurological SAE | 0.94 [0.62 1.43] | p=1.00 | 0 | 2341 | 1 | ODYSSEY Long-Term, | | Neurocognitive disorder | 2.28 [0.77 6.77] | p=1.00 | 0 | 2341 | 1 | ODYSSEY Long-Term, | | Muscle-related adverse events | no data | | cardiovascular death as adverse event | 0.38 [0.18 0.77] | p=0.04 | 0 | 3735 | 5 | ODYSSEY Long-Term,ODYSSEY Alternative,ODYSSEY HIGH FH ,ODYSSEY COMBO,ODYSSEY COMBO II, | | myocardial infarction as adverse event | 0.44 [0.22 0.85] | p=0.04 | 0 | 2908 | 3 | ODYSSEY Long-Term,ODYSSEY Alternative,ODYSSEY COMBO, | | unstable angina as adverse death | no data | | cardiovascular events | 0.87 [0.81 0.94] | p=0.04 | 0 | 18924 | 1 | ODYSSEY OUTCOMES, | | Cardiovascular death | 0.88 [0.74 1.05] | p=1.00 | 0 | 18924 | 1 | ODYSSEY OUTCOMES, | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | Coronary event | 0.88 [0.80 0.96] | p=0.04 | 0 | 18924 | 1 | ODYSSEY OUTCOMES, | | Coronary death | 0.92 [0.76 1.11] | p=1.00 | 0 | 18924 | 1 | ODYSSEY OUTCOMES, | | Allergic reactions | 1.06 [0.79 1.41] | p=1.00 | 0 | 2341 | 1 | ODYSSEY Long-Term, | | All cause death | 0.85 [0.73 0.98] | p=0.04 | 0 | 18924 | 1 | ODYSSEY OUTCOMES, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
